Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-18T22:47:16.886Z Has data issue: false hasContentIssue false
  • English
  • Français

A fatal complication of clozapine - induced agranulocytosis

Published online by Cambridge University Press:  13 June 2014

Brian Mangan  and
Martin J Toal
Brian Mangan
Affiliation:
(now Department of Mental Health, Whitla Medical Building, Belfast City Hospital)
Martin J Toal
Affiliation:
Tyrone and Fermanagh Hospital, Donaghanie Road, Omagh, Co. Tyrone BT79 ONS, Northern Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Clozapine (Clozaril-Sandoz) is an atypical anti-psychotic drug used for the treatment of resistant schizophrenia. We describe the first fatal outcome as a consequence of neutropenia in the British Isles attributed to the use of clozapine. This death occurred despite proper monitoring by the Clozaril Patient Monitoring Service (CPMS) and full clinical vigilance.

Keywords

ClozapineAgranulocytosis
Type
Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 11 , Issue 3 , September 1994 , pp. 138 - 139
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. A Guide to CPMS (3rd Ed) A reference manual for the Clozaril Patient Monitoring Service.Google Scholar
2.Krupp, P, Barnes, P. Clozapine associated granulocytopenia; risk and aetiology. Br J Psychiatry 1992; 160 (Supple) 17: 38–40.CrossRefGoogle Scholar
3.Amsler, HA, et al.Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56(4): 241–8.CrossRefGoogle ScholarPubMed
4.Idanpaan-Heikkala, J, et al.Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193–8.CrossRefGoogle Scholar
5.Krupp, P, Barnes, P. Leporex associated granulocytopenia; a review of the situation. Psychopharmacol 1989; 99: S118–121.CrossRefGoogle ScholarPubMed
6.Adams, CEet al.Agranulocytosis induced by clozapine with the early addition of trifuloperazine: a case report. Int Clin Psychopharmacol 1990; 5: 287–90.CrossRefGoogle Scholar
7.King, J. Monotherapy: always desirable, usually possible. Clozaril Newsletter; 2 [Editorial], 1992.Google Scholar
8.Lieberman, JA, et al.Clozapine-induced agranulocytosis: non cross reactivity with other psychotropic drugs. J Clin Psychiatry, 1988; 49: 271–7.Google ScholarPubMed
9.Gerson, SL, Meltzer, H. Mechanisms of clozapine induced agranolocytosis. Drug Safety 1992; 7 (Suppl. 1): 17–25.CrossRefGoogle Scholar
10.Pisciotta, AV, Konings, SA, Ciesemier, LL, Cronkite, CE, Lieberman, JA. On the possible mechanisms and predictability of clozapine induced agranulocytosis. Drug Safety 1992; 7 (Suppl. 1): 33–44.CrossRefGoogle ScholarPubMed
11.Barnas, C, et al.Granulocyte-macrophase colony-stimulating factor (GM-CSF): treatment of clozapine-induced agranulocytosis: a case report. J Clin Psychiatry 1992; 07: 53–7.Google Scholar
12.Lieberman, JA, Kane, JM, Johns, CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329–38.Google ScholarPubMed